# EDGAR Filing Document

**Accession Number:** 0001832106
**File Stem:** 0001493152-26-005412
**Filing Date:** 2026-2
**Character Count:** 31376
**Document Hash:** 26a2fb1d35e378c44e54b1e5db111624
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-005412.hdr.sgml**: 20260205

**ACCESSION NUMBER**: 0001493152-26-005412

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260205

**DATE AS OF CHANGE**: 20260205

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ProMIS Neurosciences Inc.
- **CENTRAL INDEX KEY:** 0001374339
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** Z4
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-93797
- **FILM NUMBER:** 26604552

**BUSINESS ADDRESS:**
- **STREET 1:** SUITE 200, 1920 YONGE STREET
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M4S 3E2
- **BUSINESS PHONE:** 416-847-6898

**MAIL ADDRESS:**
- **STREET 1:** SUITE 200, 1920 YONGE STREET
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M4S 3E2

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMORFIX LIFE SCIENCES LTD
- **DATE OF NAME CHANGE:** 20060831
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ABG Management Ltd.
- **CENTRAL INDEX KEY:** 0001832106

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 15 QUEENS ROAD CENTRAL, UNIT 3002-3004
- **STREET 2:** 30TH FLOOR, GLOUCESTER TWR, THE LANDMARK
- **CITY:** HONG KONG
- **STATE:** F4
- **ZIP:** 0000000000
- **BUSINESS PHONE:** 852 31219699

**MAIL ADDRESS:**
- **STREET 1:** 15 QUEENS ROAD CENTRAL, UNIT 3002-3004
- **STREET 2:** 30TH FLOOR, GLOUCESTER TWR, THE LANDMARK
- **CITY:** HONG KONG
- **STATE:** F4
- **ZIP:** 0000000000

## Ex-7

**Exhibit 7**

**JOINT FILING AGREEMENT**

In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13D. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing Agreement as of February 5, 2026.

---

| | |
|:---|:---|
| **ABG Management Ltd.** | **ABG Management Ltd.** |
| By: | /s/ Fan Yu |
| Name: | Fan Yu |
| Title: | Director |
| **Ally Bridge Group (NY) LLC** | **Ally Bridge Group (NY) LLC** |
| By: | ABG Management Ltd., its managing member |
| By: | /s/ Fan Yu |
| Name: | Fan Yu |
| Title: | Director |
| **Ally Bridge MedAlpha Master Fund L.P.** | **Ally Bridge MedAlpha Master Fund L.P.** |
| By: | Ally Bridge Group (NY) LLC, its manager |
| By: | ABG Management Ltd., its managing member |
| By: | /s/ Fan Yu |
| Name: | Fan Yu |
| Title: | Director |
| **ABG V-SIV IX Limited** | **ABG V-SIV IX Limited** |
| By: | Ally Bridge Group Global Life Science Capital Partners V, L.P., its controlling stockholder |
| By: | ABG Global Life Science Capital Partners V GP, L.P., its general partner |
| By: | ABG Global Life Science Capital Partners V GP Limited, its general partner |
| By: | /s/ Fan Yu |
| Name: | Fan Yu |
| Title: | Director |
| **Ally Bridge Group Global Life Science Capital Partners V, L.P.** | **Ally Bridge Group Global Life Science Capital Partners V, L.P.** |
| By: | ABG Global Life Science Capital Partners V GP, L.P., its general partner |
| By: | ABG Global Life Science Capital Partners V GP Limited, its general partner |
| By: | /s/ Fan Yu |
| Name: | Fan Yu |
| Title: | Director |
| **ABG Global Life Science Capital Partners V GP, L.P.** | **ABG Global Life Science Capital Partners V GP, L.P.** |
| By: | ABG Global Life Science Capital Partners V GP Limited, its general partner |
| By: | /s/ Fan Yu |
| Name: | Fan Yu |
| Title: | Director |
| **ABG Global Life Science Capital Partners V GP Limited** | **ABG Global Life Science Capital Partners V GP Limited** |
| By: | /s/ Fan Yu |
| Name: | Fan Yu |
| Title: | Director |
| **ABG V-SIV X Limited** | **ABG V-SIV X Limited** |
| By: | /s/ Fan Yu |
| Name: | Fan Yu |
| Title: | Director |
| **Fan Yu** | **Fan Yu** |
| /s/ Fan Yu | /s/ Fan Yu |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 2)**

**ProMIS Neurosciences Inc.**

*(Name of Issuer)*

**Common Shares, no par value per share**

*(Title of Class of Securities)*

**74346M505**

*(CUSIP Number)*

**Fan Yu**<br>c/o ABG Management Ltd.

#3902, 39/F, E Tower, 10 Harcourt RD CTR<br>Hong Kong K3 0000000000<br>852 31219699

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**02/03/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **74346M505** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**ABG Management Ltd.** | Name of reporting person<br>**ABG Management Ltd.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**572677.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**572677.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**572677.00** | Aggregate amount beneficially owned by each reporting person<br>**572677.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**6.3%** | Percent of class represented by amount in Row (11)<br>**6.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

| **CUSIP No.** | **74346M505** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Ally Bridge Group (NY) LLC** | Name of reporting person<br>**Ally Bridge Group (NY) LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**572677.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**572677.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**572677.00** | Aggregate amount beneficially owned by each reporting person<br>**572677.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**6.3%** | Percent of class represented by amount in Row (11)<br>**6.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** Limited Liability Company

| **CUSIP No.** | **74346M505** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Ally Bridge MedAlpha Master Fund L.P.** | Name of reporting person<br>**Ally Bridge MedAlpha Master Fund L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**572677.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**572677.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**572677.00** | Aggregate amount beneficially owned by each reporting person<br>**572677.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**6.3%** | Percent of class represented by amount in Row (11)<br>**6.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

| **CUSIP No.** | **74346M505** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**ABG V-SIV IX Limited** | Name of reporting person<br>**ABG V-SIV IX Limited** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**659520.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**659520.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**659520.00** | Aggregate amount beneficially owned by each reporting person<br>**659520.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**7.1%** | Percent of class represented by amount in Row (11)<br>**7.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

| **CUSIP No.** | **74346M505** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Ally Bridge Group Global Life Science Capital Partners V, L.P.** | Name of reporting person<br>**Ally Bridge Group Global Life Science Capital Partners V, L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**659520.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**659520.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**659520.00** | Aggregate amount beneficially owned by each reporting person<br>**659520.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**7.1%** | Percent of class represented by amount in Row (11)<br>**7.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

| **CUSIP No.** | **74346M505** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**ABG Global Life Science Capital Partners V GP, L.P.** | Name of reporting person<br>**ABG Global Life Science Capital Partners V GP, L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**659520.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**659520.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**659520.00** | Aggregate amount beneficially owned by each reporting person<br>**659520.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**7.1%** | Percent of class represented by amount in Row (11)<br>**7.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

| **CUSIP No.** | **74346M505** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**ABG Global Life Science Capital Partners V GP Limited** | Name of reporting person<br>**ABG Global Life Science Capital Partners V GP Limited** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**659520.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**659520.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**659520.00** | Aggregate amount beneficially owned by each reporting person<br>**659520.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**7.1%** | Percent of class represented by amount in Row (11)<br>**7.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

| **CUSIP No.** | **74346M505** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**ABG V-SIV X Limited** | Name of reporting person<br>**ABG V-SIV X Limited** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**412200.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**412200.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**412200.00** | Aggregate amount beneficially owned by each reporting person<br>**412200.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.5%** | Percent of class represented by amount in Row (11)<br>**4.5%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

| **CUSIP No.** | **74346M505** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Fan Yu** | Name of reporting person<br>**Fan Yu** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**O1** | Citizenship or place of organization<br>**O1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1644397.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1644397.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1644397.00** | Aggregate amount beneficially owned by each reporting person<br>**1644397.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**17.0%** | Percent of class represented by amount in Row (11)<br>**17.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Shares, no par value per share

**(b) Name of Issuer:**
ProMIS Neurosciences Inc.

**(c) Address of Issuer's Principal Executive Offices:**
Suite 200, 1920 Yonge Street, Toronto, A6, M4S 3E2

**Item 4. Purpose of Transaction**

Item 4 is amended and supplemented by the following:

CLOSING OF OFFERING

On February 3, 2026, the previously disclosed Offering closed.

REGISTRATION RIGHTS AGREEMENT

On February 3, 2026, in connection with the closing of the Offering, the Issuer entered into a registration rights agreement (the "2026 Registration Rights Agreement") with the investors in the Offering, pursuant to which the Issuer is required to prepare and file a registration statement with the Securities and Exchange Commission covering the resale of the Common Shares issued to the investors pursuant to the Securities Purchase Agreement, together with the Common Shares underlying the Warrants.

The foregoing description of the 2026 Registration Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the form-of 2026 Registration Rights Agreement, which is attached as an exhibit to this Schedule 13D and incorporated herein by reference.

REVERSE STOCK SPLIT

The amount of Common Shares reported herein reflects a 1-for-25 reverse stock split that occurred on November 28, 2025.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Item 5 is amended and restated in its entirety by the following:

The information contained on the cover pages is incorporated by reference into this Item 5.

The ownership information presented herein represents beneficial ownership of the Issuer's Common Shares, based on 8,967,693 Common Shares outstanding immediately following the closing of the Offering.

The Common Shares reported as beneficially owned herein include: (i) 407,230 Common Shares and 164,881 Common Shares issuable upon the exercise of Warrants held of record by Ally Bridge MedAlpha Master Fund L.P., (ii) 329,760 Common Shares and 329,760 Common Shares issuable upon the exercise of Warrants held of record by ABG V-SIV IX Limited and (iii) 206,100 Common Shares and 206,100 Common Shares issuable upon the exercise of Warrants held of record by ABG V-SIV X Limited.

Additionally, there are 566 Common Shares underlying an employee stock option granted to Dr. Alex by the Issuer and held by him for the benefit of Ally Bridge MedAlpha Master Fund L.P., which amount represents the number of Common Shares that are currently vested or that will vest within 60 days of the date of this filing.

The amount of securities reported herein does not include 387,600 Common Shares issuable upon exercise of warrants held of record by Ally Bridge MedAlpha Master Fund L.P., which are subject to limitations on exercise.

Mr. Fan Yu is the controlling stockholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by Ally Bridge MedAlpha Master Fund L.P.

Mr. Fan Yu is also the indirect controlling stockholder of ABG Global Life Science Capital Partners V GP Limited, which is the general partner of ABG Global Life Science Capital Partners V GP, L.P., which is the general partner of Ally Bridge Group Global Life Science Capital Partners V, L.P., which is the controlling shareholder of ABG V-SIV IX Limited.  As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV IX Limited.

Mr. Fan Yu is also the controlling stockholder of ABG V-SIV X Limited. As such, Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV X Limited.

**(b)**
The information contained on the cover pages is incorporated by reference into this Item 5.

**(c)**
Except as described in this Schedule 13D, the Reporting Persons have not effected any transactions in the Common Shares during the past sixty days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Item 6 is amended and supplemented by the following.

Item 4 above summarizes certain provisions of the 2026 Registration Rights Agreement and is incorporated herein by reference. A copy of such agreement is attached as an exhibit to this Schedule 13D and is incorporated herein by reference.

Except as set forth herein, none of the Reporting Persons has any contracts, arrangements, understandings or relationships (legal or otherwise) with any person with respect to any securities of the Issuer, including but not limited to any contracts, arrangements, understandings or relationships concerning the transfer or voting of such securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses, or the giving or withholding of proxies.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** ABG Management Ltd.

**Signature:** By: /s/ Fan Yu

**Name/Title:** Fan Yu, Director

**Date:** 02/05/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Ally Bridge Group (NY) LLC

**Signature:** By: ABG Management Ltd., its managing member, By: /s/ Fan Yu

**Name/Title:** Fan Yu, Director

**Date:** 02/05/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Ally Bridge MedAlpha Master Fund L.P.

**Signature:** By: Ally Bridge Group (NY) LLC, its manager, By: ABG Management Ltd., its managing member, By: /s/ Fan Yu

**Name/Title:** Fan Yu, Director

**Date:** 02/05/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** ABG V-SIV IX Limited

**Signature:** By: ABG Global Life Science Capital Partners V GP, L.P., ABG Global Life Science Capital Partners V GP Limited, /s/ Fan Yu

**Name/Title:** Fan Yu, Director

**Date:** 02/05/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Ally Bridge Group Global Life Science Capital Partners V, L.P.

**Signature:** By: ABG Global Life Science Capital Partners V GP, L.P., its GP, By: ABG Global Life Science Capital Partners V GP Limited, its GP, By: /s/ Fan Yu

**Name/Title:** Fan Yu, Director

**Date:** 02/05/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** ABG Global Life Science Capital Partners V GP, L.P.

**Signature:** By: ABG Global Life Science Capital Partners V GP Limited, its general partner, By: /s/ Fan Yu

**Name/Title:** Fan Yu, Director

**Date:** 02/05/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** ABG Global Life Science Capital Partners V GP Limited

**Signature:** By: /s/ Fan Yu

**Name/Title:** Fan Yu, Director

**Date:** 02/05/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** ABG V-SIV X Limited

**Signature:** By: /s/ Fan Yu

**Name/Title:** Fan Yu, Director

**Date:** 02/05/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Fan Yu

**Signature:** /s/ Fan Yu

**Name/Title:** Fan Yu

**Date:** 02/05/2026